From micro to macro, nanotechnology demystifies acute pancreatitis: a new generation of treatment options emerges

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Jan. 29, 2025

Acute pancreatitis (AP) is a disease characterized by an acute inflammatory response in the pancreas. This caused abnormal activation of pancreatic enzymes variety etiologic factors, which results localized response. The symptoms this include abdominal pain, nausea and vomiting fever. These are induced hyperinflammatory oxidative stress. In recent years, research has focused on developing anti-inflammatory antioxidative therapies for treatment (AP). However, there still limitations to approach, including poor drug stability, low bioavailability short half-life. advent nanotechnology opened up novel avenue management Nanomaterials can serve as efficacious vehicle conventional pharmaceuticals, enhancing their targeting ability, improving prolonging Moreover, they also exert direct therapeutic effect. review begins introducing general situation It then discusses pathogenesis current status treatment. Finally, it considers literature related nanomaterials. objective study provide comprehensive existing use nanomaterials particular, changes markers outcomes following administration examined. done with intention offering insights that inform subsequent facilitate clinical application

Language: Английский

---

Thrombin-Responsive and Sequential Targeted Nanoplatform for Synergistic Thrombolysis Therapy

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: March 7, 2025

Traditional thrombolytic therapy is limited by low specificity, uncontrollable bleeding complications, and secondary vascular re-embolism. To address this issue, we developed a thrombin-responsive sequential targeted nanoplatform (MMSN-UK/TI@pep-Fuco) for efficient thrombolysis based on the attack-defense-protection integrated strategy. Herein, multilevel mesoporous silica nanoparticle with multiple pore sizes was synthesized modified fucoidan (Fuco) using compound peptide (pep) as bridge to form multifunctional drug carriers MMSN@pep-Fuco. Then, urokinase (UK) tirofiban (TI) were sequentially loaded into MMSN@pep-Fuco obtain MMSN-UK/TI@pep-Fuco nano delivery systems (NDDS). In vitro in vivo results demonstrated that maintained stability blood circulation reduce risk (protection). Once arriving at thrombus clots, Fuco facilitated NDDS identification accumulation via P-selectin-mediated active targeting. Thereafter, coating surface of shed response thrombin then allowed quick release UK from larger pores achieve rapid (attack). Next, exposed LS-MMSN/TI core NPs can continue colonizing sites, TI smaller released slowly continuously prevent re-embolization vessels (defense). Pharmacodynamic showed final blockage rate treatment group only 4.87% relatively risk. This provided new strategy arterial thrombosis related diseases.

Language: Английский

---

Fibrinogen binding to activated platelets and its biomimetic thrombus-targeted thrombolytic strategies

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 274, P. 133286 - 133286

Published: June 21, 2024

Language: Английский

---

Advances in the Study of Drugs for Thrombolytic Therapy of Venous Thromboembolism

Journal of Clinical Personalized Medicine, Journal Year: 2024, Volume and Issue: 03(04), P. 2519 - 2524

Published: Jan. 1, 2024

Language: Английский

---